varian medic system inc engag
manufactur medic devic
softwar treat cancer
medic condit oper
oncolog system proton solut
design manufactur sell servic
hardwar softwar product treat
cancer convent radiat therapi
advanc
form extern beam radiotherapi use
proton beam treatment cancer
compani found william
hansen edward ginzton russel varian
sigurd varian headquart
palo alto ca
commit innov posit evolut toward
value-bas high level astro takeaway increas pt
astro varian medic held meet investor year astro confer held
chicago last week compani clearli remain commit broaden alreadi
signific footprint cancer care space highlight sever way
deliv valu care provid patient payor alik innov care
coordin initi next sever year varian new artifici
intellig ai power etho product certainli headline-grabb year
event compani continu push tradit boundari mani
import way well perhap importantli strongli believ varian
well posit potenti reimburs chang might come healthcar
includ cancer care continu evolv toward value-bas model
etho varian adapt person etho therapi system treat first patient
hospit herlev denmark two week ago system effect
visual chang patient anatomi quickli adapt radiat treatment align
chang treatment still accomplish within typic
minut timeslot addit wit demonstr would strongli suggest
etho patient-centr term meaning increas physic
space patient receiv treatment well quiet deliveri treatment
strongli suspect radiat deliv via etho system receiv
high mark clinician patient alik etho current ce mark
regulatori clearanc still pend
flash flash therapi continu hold great promis remind flash therapi
deliv high dose radiat less one second shown greatli
reduc damag healthi tissu organ versu tradit proton treatment
preclin work convict around potenti flash repres ground-
break paradigm shift treatment cancer grown throughout
cancer treatment clinic health outcom patient throughput
prepar value-bas price continu consid best way
reimburs radiat oncolog final rule expect novemb said
clear varian take step within extern growth initi
prepar futur item total cost care versatil treatment
coordin care provabl value-add health outcom engag
patient increasingli measur assess within reimburs framework
recommend continu rate share outperform increas
price target previous arriv price target attach
multipl adjust ebitda estim price target assum
approxim million net cash month
pleas see end report begin page import disclosur
revenu
interest incom net
 revenu
sg revenu
pre-shar repo chg wc
million except per share data
 xp ec ted per form ark ext th
 ote tia exi st ar -te ata yst
 xp ec ted pe rform ro hli rket th ne nth
lon -te otenti xi ts bu ne ar -te rm catali
 xp ec ted un de perfo rm rk et ov er ne xt th
com ny fu nd ta ls deteri ra tin
fu va lue ov r- va lu ed cur ren level
 lop ri ce tar ge fo thi co pa ny se /e da ho
ri ks tha ou ta rg ri ce wi achi he clu de ot im ite fai lure
co et ue ar nin stim ate
th fo wi ng li ra tin gs fo co pa nie co ed rr ton ear ch cia te
inc ju ne ber om pa ate tp fo
rep rese te al co ni es th ov ra ge ist th num co pa ate
 rf rm nd re nted co pa ni es th cover ag ist
th um com ni rate un rp fo wa se nte al
comp ie th ov er ge list lso un rri ngto se rch cia te
inc rov id nvestm en ba kin se rv ice ith th la st th
co pa es th ha tp ra tin gs co ani th ha
 rf rm ti gs com es th ha nd rf rm
na lyst er tific ion se rc na yst sp on ib le fo th arat th es ea rch po ich el etusk fa rebi certi fi es
th vi ew ab ut om nie nd th ei secur iti xp ss ed th ort ccu ate eflect hi er op ni ns lyst lso
ce rti fi th rt hi com pen sa ti di ctl ind ir ectli rel te th pe ci fic co mm en ati vie co ta ed th ort
 es ea rch lyst cl di tho vo lv ed ep ar ati thi rep rt ce ive ct om pe sa tio co ne cti wi th firm
stm ank ctivi tie na ly st co en ati wh ich de sa la ry nu ba se ume ou fa ctor clu din
stock pr ice erfo ce al iti al ysi nv esto cl ie nt feed ack ell th ral ro fitab il iti th fi rm wh ch mp act
 th firm us ess acti viti cl ude ng th gs in tituti onal qu iti tr ing nv es tme ba nk se rvi ce
stm en nking ser vic es de fi ne un er le cl es thi gs ac ting un de wri ter er
 lli ng gro se cu ri tie de rw riti al yst sp si ble th rt hael tu sk fa em th alyst
 ou eho ld doe sh th co stock th com pan ula tio ted le th proh ib se arc ana yst
trad se curi tie co co es dur sp ec ifi tim er io ds efor aft th pu bli ca tion re rch ep rt
 rr gton esea rch sociat inc full -se vic fi na ci al se vic es firm th off rs wid va ieti se vic es pr du ts lie ts
stor sh ld ass ume rr ing ton ear ch ee ing ill se ek investm nt ba kin th us ess rela ti onshi ps ith th
co es de ts se rc co er rin gton se arc rece iv ed nve tmen ki g- rel ate com en sa tio fro thi
co ith th pa st onth exp ct wi th th ne xt th mo nth
barrington research associ inc finra-regist broker/deal clear wedbush secur fulli
disclos basi conveni client offer sever way client facilit payment
trade barrington research order may place trade desk
trader michael hutchison head trader christoph pari email address
instant messeng address brrrmh
trade broker trade may also stepped-in barrington research trade execut broker
commiss share arrang barrington commiss share agreement numer broker wall
street complet list commiss share program barrington research particip pleas contact
salesperson trade desk
follow list provid barrington research trade alloc settlement id wedbush dtc code
question trade set account relat inform pleas call trade depart
inform contain herein obtain sourc believ reliabl guarante accuraci complet
opinion estim reflect best judgment report date subject chang without notic report intend inform
purpos constitut offer solicit buy sell secur barrington research associ inc affili offic
analyst employe may time time posit secur refer herein barrington research associ inc may act
princip agent buyer seller purchas sale secur mention report barrington research associ
inc may provid may seek provid invest bank servic compani mention report report may
reproduc form without prior written consent barrington research associ inc right reserv member finra/sipc
